Botox for Treatment of TMJ Disorder With Bruxism (TMJ)

• ClinicalTrials.gov Identifier: NCT02202070
• Recruitment Status: Withdrawn
• First Posted: July 28, 2014
• Last Update Posted: January 23, 2018
• Sponsor: Washington University School of Medicine
• Information provided by (Responsible Party): Ethan Baughman, Washington University School of Medicine

Study Description

Brief Summary:

Hypothesis: Myofascial temporomandibular joint disorder and related symptoms are associated with mandibular condyle and temporal fossa overloading secondary to temporalis and masseter muscle hyperactivity and spasm

This study will examine the use of onabotulinumtoxinA (Botox) to treat myofascial pain disorder in patients with bruxism who frequently exhibit signs of temporomandibular joint disorder (TMD) in a double blind cross-over randomized clinical trial by injecting 50 units Botox in temporalis and masseter muscles in 32 patients with 6 months follow up.

The objective of the proposed study will be to establish the safety and efficacy of botox in treating TMD associated with bruxism. By the time patients reach the specialists office, most have failed maximal conservative therapies, including non-chew diet, night guard, oral analgesics, muscle relaxants, physical therapy, and a portion have even undergone more invasive procedures, such as manipulation under anesthesia, arthroscopy, and arthroplasty surgeries with limited improvement or recurrence. Primary outcome of the study will be 50% reduction in pain. Secondary outcomes will be 50% reduction in surgical therapy, 25% increase in maximal inter-incisal opening (MIO). The investigators look forward to working with you on the proposed study

Condition or disease	Intervention/treatment	Phase
Temporomandibular Joint Disorders; Bruxism; Temporomandibular Joint Dysfunction Syndrome; Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint	Drug: onabotulinumtoxinA	Phase 1

Detailed Description:

The study will enroll 32 patients with myofascial TMD. Patient will be aged 18-65. Exclusion criteria will include neuromuscular diseases, prior botox injections within previous 12 months, pregnancy, and fibromyalgia. All patients will be selected from the outpatient clinic, complaining of TMJ disease associated with bruxism. Screening will include a thorough history and exam, and TMJ CT scan or MRI. Patients with neuromuscular disorders, musculoskeletal disorders, and prior Botox injections will be excluded. Patients who have not already undergone conservative treatment will be managed with 3 months conservative therapies prior to becoming eligible. All patients will be informed and consented for participation in the study and Botox injections. Baseline pain questionnaire, physical exam will be performed. Patients will be randomized to receive normal saline or botox injections. All patients will crossover for the second set of injections at 3 months. All patients will receive up to a total of 200 Botox units at either 0 or 3 month time points. In this regard, patients will act as their own placebo control. Botox will be prepared according to the manufacturer's instructions. Briefly, the lyophilized protein will be reconstituted with preservative-free normal saline and drawn into 1-mL syringe. While the patient is sitting in the office procedure chair, 25 to 50 U of Botox will be injected into each temporalis muscle and 25 to 50 U of Botox will be injected into the each masseter muscle. The patient will be instructed to keep head elevated for 8 hours. Patients will be called 3 times after the first round of injections, to monitor for adverse events. Patients will be seen in clinic at 3 months and asked to fill out a second pain questionnaire. They will also undergo second physical exam, and then receive a second set of injections (crossover). Patients will be seen in clinic at 6 months and asked to fill out a third pain questionnaire undergo third physical exam. Patients will be called 3 times after the second round of injections, to monitor for adverse events. Patients will be seen in clinic at 6 months and asked to fill out a third pain questionnaire undergo a third physical exam

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Double (Participant, Care Provider)
• Primary Purpose: Treatment
• Official Title: Phase 1 Study of Role of Botox in Myofascial Temporomandibular Disorder
• Actual Study Start Date: January 2015
• Actual Primary Completion Date: December 2015
• Actual Study Completion Date: December 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Botox injection first, followed by placebo; 50 units Botox injection in masseter and temporalis muscles in the first 3 months, then second injection of normal saline at placebo in second 3 months	Drug: onabotulinumtoxinA; Other Name: BOTOX
Experimental: Placebo injection first, followed Botox; Injection of normal saline at placebo in first 3 months, then 50 units Botox injection in masseter and temporalis muscles in the second 3 months.	Drug: onabotulinumtoxinA; Other Name: BOTOX

Outcome Measures

Primary Outcome Measures :

1. 50% reduction in pain [ Time Frame: 6 months ]
   Patients will be seen in clinic every 3 months and asked to fill out questionaire. Questionaire will include with visual analogue scale (VAS) average pain over previous week, month

Secondary Outcome Measures :

1. 25% increase in maximal opening at incisors [ Time Frame: 6 months ]
   Patients will be seen in clinic every 3 months. Providers will objectively measure maximal opening at incisors (MOI), lateral and anterior mandible excursion on clinical exam.

Other Outcome Measures:

1. 50% reduction in progression of disease to surgery [ Time Frame: 6 months ]
   Patients will be monitored for TMJ arthoscopic and arthoplasty procedures

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• aged 18-65 persons with a diagnosis of myofascial temporomandibular joint disorder refractory to conservative treatment for 6 months

Exclusion Criteria:

• pregnancy
• rheumatoid arthritis
• ankylosing spondylitis
• psoriatic arthritis
• fibromyalgia
• neuropathic pain
• pain of dental origin
• muscle relaxant use
• aminoglycoside use
• prior Botox use
• neuropathic pain
• trigeminal neuralgia

Contacts and Locations

Locations

United States, Missouri

Washington University School of Medicine

Saint Louis, Missouri, United States, 63110

Sponsors and Collaborators

Washington University School of Medicine

Investigators

• Principal Investigator: Alan A Harvey, DMD; Assistant Professor, Department of Otolaryngology

More Information

Additional Information:

University Oral & Maxillofacial Surgeons 

• Responsible Party: Ethan Baughman, Plastic surgery resident physician, Washington University School of Medicine
• ClinicalTrials.gov Identifier: NCT02202070
• Other Study ID Numbers: AAHEJB
• First Posted: July 28, 2014
• Last Update Posted: January 23, 2018
• Last Verified: January 2018

Keywords provided by Ethan Baughman, Washington University School of Medicine:

onabotulinumtoxinA; Temporomandibular Joint Disorders; Bruxism; Temporomandibular Joint Dysfunction Syndrome; Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint

Additional relevant MeSH terms:

Joint Diseases; Temporomandibular Joint Disorders; Temporomandibular Joint Dysfunction Syndrome; Fibromyalgia; Myofascial Pain Syndromes; Bruxism; Disease; Syndrome; Pathologic Processes; Tooth Diseases; Stomatognathic Diseases; Musculoskeletal Diseases; Craniomandibular Disorders; Mandibular Diseases; Jaw Diseases; Muscular Diseases; Rheumatic Diseases; Neuromuscular Diseases; Nervous System Diseases; Botulinum Toxins, Type A; abobotulinumtoxinA; Neuromuscular Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Acetylcholine Release Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Cholinergic Agents; Neurotransmitter Agents